iRhythm (IRTC) Q1 2026 earnings review
Guidance Raised as Volume Growth Scales, But Cash Burn Reverses Course
iRhythm delivered a robust start to 2026, posting 25.7% YoY revenue growth to $199.4M and raising full-year top and bottom-line guidance. The core thesis—that Zio volume growth will translate to operating leverage—is playing out, with gross margins expanding 210 basis points YoY to 70.9%. However, after celebrating its first-ever positive net income and free cash flow in late 2025, Q1 saw a sequential reversing back to a $13.9M net loss and a sharp $33.1M free cash flow burn. While management cites typical seasonality and investments, the cash burn and rising litigation costs show the path to sustained GAAP profitability will not be perfectly linear.
🐂 Bull Case
Volume-led revenue growth of 25.7% YoY proves durable momentum across cardiology, primary care, and innovative channels. The raise in FY26 guidance indicates management's confidence in continued market share gains.
Adjusted EBITDA margin improved by a massive 880 basis points YoY to 7.1%. Economies of scale are successfully dropping to the bottom line on an adjusted basis.
🐻 Bear Case
Free cash flow was deeply negative at -$33.1M, worse than the -$17.3M burned in the same period last year. Operating cash flow reversed sharply from the positive momentum seen in H2 2025.
Intellectual property litigation expenses related to Baxter subsidiaries jumped to $3.7M in the quarter (up from $0.8M a year ago), representing a continuous non-operational cash drain.
⚖️ Verdict: 🟢
Bullish. Despite the sequential cash flow dip—which is characteristic of the company's Q1 seasonality—the core operational engine is firing on all cylinders. A guidance raise this early in the year is a strong signal of commercial health.
Key Themes
Volume-Led Core Growth Remains Stable
Revenue grew 25.7% YoY to $199.4M. This represents a stable, highly elevated growth trajectory following late 2025's performance. Growth is well-diversified, driven by the core Zio monitor, the higher-acuity Zio AT, and penetration into international markets and innovative health channels.
Gross Margin Expansion
Gross margin accelerated to 70.9%, up 210 basis points compared to 26Q1. This was driven primarily by operational efficiencies and scale benefits from higher volumes, validating management's long-term margin targets.
AI and Upstream Detection
iRhythm continues its strategic push to move diagnosis upstream into primary care. Management explicitly highlighted advancing AI-enabled capabilities as a key tool to unlock a significantly larger total addressable market while lowering the total cost of cardiac care.
Q1 Sequential Profitability Reversal
After achieving its first-ever GAAP net income in 25Q4 (+$5.6M), profitability reversed, with the company posting a net loss of $13.9M in 26Q1. While this is a massive YoY improvement (from a $30.7M loss in 25Q1) and typical for Q1 seasonality, it breaks the string of sequential GAAP improvements and reminds investors that consistent GAAP profitability is still a work in progress.
Mounting IP Litigation Costs
Intellectual property litigation costs (excluded from Adjusted EBITDA but very real to cash flow) surged to $3.69M in the quarter, up sharply from $0.83M in 25Q1. These expenses relate to ongoing patent litigation with Welch Allyn/Bardy Diagnostics (Baxter subsidiaries) and represent a growing headwind to free cash flow generation.
Free Cash Flow Burn Reverses Course
Free cash flow for the quarter was deeply negative at -$33.1M, a reversing trend compared to the positive FCF generated in late 2025. This was driven by a $26.2M operating cash outflow and $6.9M in capital expenditures. Notably, the cash burn was worse than the -$17.3M FCF recorded in the same period last year, indicating working capital pressures or timing of payments.
Other KPIs
Grew 9.3% YoY from $140.4M. Importantly, this growth rate is significantly slower than the 25.7% revenue growth rate, demonstrating excellent operating leverage. Management attributed the absolute dollar increase to volume-related costs and investments for future growth.
The balance sheet remains highly liquid, providing ample runway. The balance decreased slightly from year-end 2025 due to the Q1 operating cash burn, but the company retains significant flexibility to fund its operations and pipeline (like the next-gen Zio MCT) without near-term capital needs.
Guidance
Accelerating. The guidance was raised from the preliminary $870M-$880M provided during the Q4 call. The midpoint ($880M) implies 17.8% YoY growth compared to FY25. While this implies a slight deceleration from Q1's 25.7% pace (likely due to base effects and typical conservatism), the raise indicates strong pipeline visibility.
Accelerating. Raised from prior guidance of 11.5% - 12.5%. This is a significant step up from the 9.2% margin achieved in FY25, highlighting management's commitment to dropping incremental revenue to the bottom line.
Key Questions
Free Cash Flow Dynamics
Operating cash flow saw a sharp negative swing in Q1, driving free cash flow burn of $33M. How much of this is related to typical Q1 working capital timing versus strategic inventory build, and when do you expect to return to the positive FCF generation seen in late 2025?
Litigation Expense Outlook
With IP litigation costs jumping to $3.7M this quarter, what is the expected cadence of these legal expenses for the remainder of 2026, and is there an updated timeline for resolution?
Next-Gen Zio MCT Timeline
Given the raised revenue guidance and continued strength of the current Zio AT offering, has there been any shift in the timeline or FDA engagement regarding the launch of the next-generation Zio MCT expected in 1H 2027?